News&lnfo
RecBio is a high-tech enterprise jointly founded by the former vaccine R & D expert team from the Chinese Center for Disease Control and Prevention (China CDC) and the senior vaccine industrialization team.
The company has established a leading domestic R & D and innovation platform for new adjuvants, genetic engineering, and immune evaluation.

20190328

  • Categories:企业里程碑
  • Author:
  • Origin:
  • Time of issue:2019-03-28
  • Views:0

(Summary description)On March 28, 2019, the Phase I clinical trial of recombinant 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58) (Hansenula polymorpha) was initiated.

20190328

(Summary description)On March 28, 2019, the Phase I clinical trial of recombinant 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58) (Hansenula polymorpha) was initiated.

  • Categories:企业里程碑
  • Author:
  • Origin:
  • Time of issue:2019-03-28
  • Views:0
Information

On March 28, 2019, the Phase I clinical trial of recombinant 9-valent HPV vaccine (HPV types-6/11/16/18/31/33/45/52/58) (Hansenula polymorpha) was initiated.

Scan the QR code to read on your phone

Previous: 20190124
Previous: 20190124
  • TOP   

Contact Us

底部联系方式

Time of issue:2022-03-29 08:59:20

Jiangsu Recbio Technology Co., Ltd.

Media Inquiry: media@recbio.cn

Investor Inquiry: ir@recbio.cn

 

Address: Vaccine Engineering Center, China Medical City, Taizhou

Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd.  All rights reserved.      苏ICP备19043567号-1